Arteaga CL - Search Results

1

ER⁺ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.

Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, André F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL. Guerrero-Zotano AL, et al. Among authors: arteaga cl. Clin Cancer Res. 2018 Jun 1;24(11):2517-2529. doi: 10.1158/1078-0432.CCR-17-2904. Epub 2018 Mar 26. Clin Cancer Res. 2018. PMID: 29581135 Free PMC article.

2

p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.

Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD, Stewart SJ. Arteaga CL, et al. Cancer Res. 1994 Jul 15;54(14):3758-65. Cancer Res. 1994. PMID: 7913407

3

Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor alpha-Pseudomonas exotoxin 40 fusion protein.

Arteaga CL, Hurd SD, Dugger TC, Winnier AR, Robertson JB. Arteaga CL, et al. Cancer Res. 1994 Sep 1;54(17):4703-9. Cancer Res. 1994. PMID: 8062268

4

Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice.

Arteaga CL, Holt JT. Arteaga CL, et al. Cancer Res. 1996 Mar 1;56(5):1098-1103. Cancer Res. 1996. PMID: 8640767

5

Predominant cytosolic localization of type II transforming growth factor beta receptors in human breast carcinoma cells.

Koli KM, Arteaga CL. Koli KM, et al. Among authors: arteaga cl. Cancer Res. 1997 Mar 1;57(5):970-7. Cancer Res. 1997. PMID: 9041203

6

Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.

Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL. Kurokawa H, et al. Among authors: arteaga cl. Cancer Res. 2000 Oct 15;60(20):5887-94. Cancer Res. 2000. PMID: 11059787

7

ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.

Lenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL. Lenferink AE, et al. Among authors: arteaga cl. Cancer Res. 2001 Sep 1;61(17):6583-91. Cancer Res. 2001. PMID: 11522658

8

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Moulder SL, et al. Among authors: arteaga cl. Cancer Res. 2001 Dec 15;61(24):8887-95. Cancer Res. 2001. PMID: 11751413

9

Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.

Kurokawa H, Arteaga CL. Kurokawa H, et al. Among authors: arteaga cl. Clin Cancer Res. 2001 Dec;7(12 Suppl):4436s-4442s; discussion 4411s-4412s. Clin Cancer Res. 2001. PMID: 11916237 Review.

10

Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Yakes FM, et al. Among authors: arteaga cl. Cancer Res. 2002 Jul 15;62(14):4132-41. Cancer Res. 2002. PMID: 12124352

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

425 results

Search Page

Filters